Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects

Trial Profile

A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Taselisib (Primary)
  • Indications Breast cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Genentech
  • Most Recent Events

    • 12 Mar 2016 Results (n = 54) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 31 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Feb 2014 Planned number of patients changed from 36 to 56 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top